Form 8-K Filing - Dyne Therapeutics, Inc.

On December 22, 2025, Dyne Therapeutics, Inc. announced the election of Vikram Karnani to its Board of Directors. Mr. Karnani will serve as a Class II director until the 2028 Annual Meeting of Stockholders. The Board has determined that Mr. Karnani meets the criteria for an independent director under Nasdaq Stock Market rules. He will receive compensation according to the Company’s non-employee director compensation program. This includes an option to purchase 59,665 shares of common stock at $20.78 per share, vesting over three years, with accelerated vesting upon a change in control. Additionally, Mr. Karnani will receive an annual cash compensation of $45,000, annual equity grants, and reimbursement for travel expenses related to Board meetings. Mr. Karnani has no existing arrangements or relationships with the Company that require disclosure under Item 404(a) of Regulation S-K and will enter into the Company’s standard indemnification agreement.